Engflag

Moxal Plus

Quick links to important sections

Moxal Plus

Moxal Plus_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moxal Plus

Property Description
Active Ingredients Aluminium Hydroxide, Magnesium Hydroxide, Simethicone
Form Oral Suspension and/or Chewable Tablet
Pharmacological Class Gastrointestinal Agent (Antacid and Antiflatulence)
Origin Synthetic Compounds
Route of Administration Oral

Moxal Plus is a combination drug product specifically designed for managing common discomforts of the upper gastrointestinal tract. This Gastrointestinal Agent is a unique formulation that integrates three separate active ingredients to provide comprehensive relief, classifying it as both an Antacid and an Antiflatulence Agent.

What Type of Combination Medicine is Moxal Plus?

Moxal Plus belongs to the therapeutic category of Gastrointestinal Agents, defined by its dual action against stomach acidity and trapped gas. It is a non-systemic formulation composed of synthetically prepared compounds that function locally within the stomach and intestines. This classification, incorporating agents for both acid neutralization and defoaming, is a common strategy in pharmaceutical design for treating multiple symptoms concurrently. Distinctively, the formulation’s composition (Aluminium and Magnesium Hydroxides plus Simethicone) is structurally similar to well-known global combination antacids, such as Maalox or Mylanta, differentiating it from single-agent products.

Composition and Physical Form of Moxal Plus

The medicine's efficacy relies on three core active ingredients: Aluminium Hydroxide, Magnesium Hydroxide, and Simethicone. Both Aluminium Hydroxide and Magnesium Hydroxide are classified as basic inorganic salts used for their complementary acid neutralization properties. The pairing of these two antacids is utilized to balance their intrinsic properties, mitigating the tendency of a single-salt antacid to cause issues such as constipation or diarrhea. Concurrently, Simethicone is an anti-foaming agent. Moxal Plus is typically available for the oral route as an oral suspension or a chewable tablet, allowing for the rapid delivery of the ingredients directly to the site of discomfort.

General Purpose: Symptomatic Relief of Gastric Distress

The general purpose of Moxal Plus is to provide rapid symptomatic relief by addressing the dual sources of discomfort: hyperacidity and flatulence. A typical use scenario involves easing acute heartburn or feelings of painful bloating after meals. The combined action ensures that the burning sensation associated with excess stomach acid is quickly buffered, while the Simethicone component simultaneously works to break down the painful gas bubbles that cause pressure. This makes it a multi-faceted solution focused purely on easing immediate digestive discomfort.

What side effects are possible with Moxal Plus?

Possible Side Effects and Safety Information

The safety profile of Moxal Plus is based on officially documented adverse reactions, limitations, and restrictions from authoritative government regulatory sources.

Adverse Reactions and Frequency

Adverse reactions are generally uncommon at recommended doses, primarily affecting the gastrointestinal system:

  • Uncommon: Diarrhea or constipation.
  • Not Known (frequency cannot be estimated): Hypersensitivity reactions (such as rash, pruritus, angioedema, or anaphylactic shock), abdominal pain, hypophosphatemia, and hyperaluminemia.

Clinically Significant and Serious Risks

Serious risks are primarily associated with prolonged use or in specific patient populations:

  • Electrolyte Imbalance: Hypophosphatemia (phosphate depletion) can occur with high doses, prolonged use, or in patients with a low-phosphorus diet. This depletion may lead to increased bone resorption and osteomalacia.
  • Systemic Toxicity: Hypermagnesemia and Hyperaluminemia are serious risks, especially in individuals with renal impairment. Long-term exposure to high levels of aluminum and magnesium in these patients can potentially lead to severe neurological or bone conditions, including encephalopathy, dementia, or microcytic anemia.

Safety Restrictions and Contraindications

Official regulatory documents define strict limitations on the use of this medicine:

  • Contraindications: Moxal Plus is formally restricted in patients with severe renal failure/kidney disease, known hypophosphatemia, or a history of hypersensitivity to any of its active components (aluminum hydroxide, magnesium hydroxide, simethicone) or excipients.
  • Use-Related Caution: Caution is required in patients with porphyria undergoing hemodialysis, and in individuals who are weak or debilitated. Prolonged use should be avoided as it may mask symptoms of more serious underlying diseases. Due to potential drug interactions, this medicine may affect the absorption of certain antibiotics and other medications.

Overdose and Emergency Response

The official regulatory profile for an overdose of this combination product documents both acute gastrointestinal manifestations and systemic risks.

Documented Overdose Presentations

Acute overdose may present with common gastrointestinal symptoms, including diarrhoea, abdominal pain, and vomiting. Larger doses may lead to severe hypomotility, potentially resulting in intestinal obstruction or ileus. The major concern with high exposure is the absorption of excess cations, which can cause systemic effects such as Hypermagnesemia and Hyperaluminemia.

Severe Outcomes and Risk Factors

Severe outcomes are strongly associated with patients who have renal impairment. In these individuals, the compromised ability to excrete magnesium and aluminum significantly elevates the risk of life-threatening systemic complications. These complications include metabolic disturbances and neurological toxicity, such as Encephalopathy and Dementia, especially after prolonged high-dose exposure. The official labeling also notes that the elderly are at increased risk for obstruction.

Official Emergency Actions

In the event of suspected overdosage, the regulatory guidance mandates that immediate steps be taken. Individuals must seek emergency medical attention or contact a Poison Control Center without delay. Management may include supportive procedures such as rehydration and forced diuresis to promote elimination. For severe systemic toxicity, intervention procedures like Haemodialysis and the use of IV Calcium Gluconate are documented components of the required medical response.

Therapeutic Uses of Moxal Plus

What Moxal Plus Treats: Main Uses and Benefits

Moxal Plus is commonly used to help with symptomatic relief across key therapeutic domains of discomfort. This medication is generally applied across domains where additional symptomatic support is needed in contexts marked by increased discomfort or tension. It helps address groups of symptoms that may appear suddenly or fluctuate.

The medicine plays a role in managing conditions characterized by periods of heightened symptoms, including heartburn, acid indigestion, sour stomach, and gas-related symptoms like pressure, fullness, and bloating. These uses align with therapeutic areas involving heightened symptom expression.

“This medication is commonly used to help ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

It assists with maintaining functional stability when symptoms interfere with daily comfort. This supportive relief is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is appropriate. The primary role of Moxal Plus is commonly used when short-term symptomatic assistance is needed.

Quick Fact: Support for Acute Symptomatic Manifestations The primary role of Moxal Plus is to provide supportive relief in situations involving certain distressing symptoms.

Regulatory References

  1. U.S. National Library of Medicine (NIH) DailyMed overview

Eligibility and Restrictions for Use

Moxal Plus eligibility is strictly defined by regulatory documents, establishing clear patient exclusions and limitations.

Populations Prohibited from Use (Contraindications)

Official regulatory documents state that Moxal Plus must not be used by individuals with the following conditions:

  • Known Hypersensitivity (allergy) to aluminium hydroxide, magnesium hydroxide, simethicone, or any excipients.
  • Kidney Failure (severe renal failure), due to the risk of systemic toxicity from accumulating aluminium and magnesium.
  • Hypophosphataemia (low blood phosphate levels).
  • Severe Debilitation (feeling very weak/no energy).
  • Hereditary Fructose Intolerance (HFI), due to the sorbitol content in some formulations.

Use Limitations and Special Populations

  • Renal Impairment: Patients with impaired kidney function must avoid prolonged use to prevent the risk of aluminium and magnesium accumulation, which can cause serious complications.
  • Pregnancy: The medicine is not to be used during the first three months of pregnancy. Use later in pregnancy must be deemed essential by a physician.
  • Children: Use in children under 12 generally requires consulting a physician. Infants (under 2 years) are at a higher risk of hypermagnesemia, especially if they have renal impairment, requiring extreme caution.
  • Low-Phosphorous Diet: Medical advice is recommended for long-term use, as the medicine can increase the risk of phosphate depletion.

What should I know about interactions with other medicines?

Moxal Plus Interactions with Other Medicines and Products

The interaction profile of Moxal Plus (Aluminium Hydroxide, Magnesium Hydroxide, Simethicone) is documented in official regulatory sources to primarily involve interference with the absorption of other orally administered medications.

Contraindicated and Restricted Combinations

Certain combinations are classified as either contraindicated or requiring strict avoidance due to the risk of severely reduced effectiveness:

  • Kinase Inhibitors: Co-administration with drugs like Pazopanib and Eltrombopag is advised against.
  • Integrase Inhibitors: Use with certain Integrase Inhibitors (e.g., Raltegravir) should be avoided.
  • Tetracycline Antibiotics: Concomitant use with Tetracycline-class antibiotics is prohibited.

Exposure and Timing Constraints

The product reduces the systemic exposure of many oral drugs (e.g., Fluoroquinolones, Digoxin, Bisphosphonates, Iron supplements) through cation binding and altered gastric pH.

Timing Constraint Requirement
General Oral Medicines Stagger administration by at least 2 hours (before or after the antacid).
Fluoroquinolone Antibiotics A longer separation of at least 4 hours is mandatory.

Population and Product-Specific Cautions

  • Citrate-Containing Products: Co-administration with Citrates (e.g., Citric Acid) is officially documented to increase serum Aluminium concentration.
  • Renal Impairment: Patients with renal impairment face a heightened risk of hyperaluminemia and hypermagnesemia, making the Citrate interaction especially critical. The combination with Polystyrene Sulphonate also carries a risk of metabolic alkalosis in this population.

Mechanism of Action

The mechanism of Moxal Plus is defined by the coordinated, non-systemic action of its three components, modulating the local chemical and physical environment within the gastrointestinal lumen. This effect is achieved across two principal mechanistic domains.

The first domain is Local Chemical Neutralization. Basic salts, specifically Magnesium Hydroxide and Aluminium Hydroxide, react directly with Hydrochloric Acid ( HCl) to consume the acid and cause an immediate rise in local pH. This shift in gastric pH consequentially leads to the functional inhibition of the proteolytic enzyme Pepsin, whose activity is restricted to highly acidic conditions. This mechanism results in diminished chemical activity against mucosal tissue.

The second domain is Physical Surface Modulation. Simethicone acts as a defoaming agent by lowering the surface tension of the gas-liquid interface. This causes unstable foam films and small, trapped gas bubbles to rupture and coalesce into larger, more mobile gas masses. This mechanical action facilitates the body's physiological mechanisms of gas expulsion. Furthermore, the combination of the two antacids exerts an antagonistic influence on gastrointestinal fluid balance, counterbalancing the individual fluid-modulating effects of each salt.

Dosage and Administration Information

How to Use Moxal Plus: Official Administration Guidelines

These instructions outline the proper administration of Moxal Plus (an antacid suspension containing Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone) as defined by official regulatory labeling. All usage must strictly adhere to the dosing and procedural steps established in regulatory prescribing information.

Administration Scope

Rule Instruction
Route of administration Oral administration
Official Dosing Adults and Children 12+: 2 to 4 teaspoonfuls (10 mL to 20 mL) per dose.
Timing in relation to meals Typically taken after meals (20 minutes to 1 hour) and at bedtime, or as required.
Maximum Use Do not take the maximum dose for more than 2 weeks unless directed by a healthcare professional.

Procedural Instructions

  • Preparation: The oral suspension must be shaken well immediately before measuring and administering the dose to ensure active ingredients are uniformly distributed.
  • Measuring: The dose must be accurately measured using a suitable device, such as a dosing spoon or cup, to ensure the correct volume (mL or tsp) is taken.
  • Drug Staggering: Antacids can affect the absorption of other medications. To prevent this, the administration of Moxal Plus should be separated from certain other oral drugs by at least 2 hours (or more, as directed by a healthcare provider for specific interacting drugs).

Age-Group Rules

  • Children under 12 years: Use in this population requires consultation and direction from a physician.
  • Elderly: The standard adult dose is generally considered appropriate, though caution is required for individuals with specific conditions, such as renal impairment.

The established protocol defines the specific frequency, volume, and timing required for use, alongside mandatory preparation steps and critical separation from other medications.

Recent Clinical Evidence

Research evidence / Overview of Studies for Moxal Plus

Evidence for Symptomatic Relief of Hyperacidity (Heartburn and Acid Indigestion)

Research has explored how the components of Moxal Plus, particularly the antacids, was studied for outcomes related to physical discomfort such as heartburn and acid indigestion. This research has been primarily conducted using short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials were typically applied in studies examining patient-reported experiences in adults who were having episodic or acute acid episodes. In addition to self-reported symptoms, studies also monitored physiological effects by measuring the change in stomach acidity ( pH levels).

Findings describe patterns observed in the studies related to how the components were studied in relation to acid levels. Research highlights changes measured during the study period, including how outcomes related to episodic or acute changes in patient discomfort evolved over the hours immediately following a dose. Long-term effects are not fully established, as follow-up durations were limited in these trials.

Evidence for Symptomatic Relief of Flatulence (Gas, Pressure, and Bloating)

Research has explored how the combination medicine was studied in research examining patient-reported experiences of outcomes related to physical discomfort such as bloating and abdominal pressure. These studies often used short-term RCTs and observational settings in subjects with conditions characterized by fluctuating or episodic manifestations of gas. The outcomes measured included patient-reported outcomes describing perceived discomfort related to gas.

Findings were mixed across some studies, particularly those focusing solely on the anti-gas component (Simethicone) in certain clinical settings. Evidence is limited regarding the performance of the anti-gas component when administered in combination versus when administered alone. Sample sizes were modest in some of the research, and as with the hyperacidity research, long-term effects are not fully established regarding the continuation of observed symptom patterns or patterns with consistent use.

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, particularly for the Simethicone component, where some findings have been mixed. Additionally, the results apply only to the populations studied, and there is limited information for long-term outcomes beyond the acute phase of symptom relief. The evidence does not provide comprehensive data comparing it to long-term therapies for chronic conditions. Data for certain groups remain insufficient, meaning the research does not determine whether individuals in specific patient groups will respond similarly.

Key Studies & References

  1. DailyMed: ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, AND DIMETHICONE suspension (FDA-required labeling for OTC combination product)

Frequently Asked Questions (FAQ)

Common questions about Moxal Plus (FAQ)

Q: Can I take Moxal Plus with my blood pressure medicine?

A: Regulatory information indicates that Moxal Plus, like other antacids, can affect the way many oral prescription medicines are absorbed. This happens by binding to the drugs or altering stomach pH. To minimize the risk of a potential interaction, official guidance advises separating the administration of the antacid from other oral medicines by at least two hours. For specific medications, it is important to discuss all concurrent medications with a healthcare professional.

Q: Is Moxal Plus the same as Maalox or Gaviscon?

A: Moxal Plus is structurally similar to certain well-known antacids, such as Maalox, as it contains the same core active ingredients: aluminum hydroxide, magnesium hydroxide, and simethicone. Gaviscon, however, often uses a different mechanism involving alginic acid. Official drug labels confirm the specific components used for dual relief but do not offer direct brand comparisons.

Q: Does Moxal Plus cause constipation or diarrhea?

A: Official safety data lists both diarrhea and constipation as uncommon, potential adverse reactions. Regulatory data indicates that the two antacid components may contribute to both constipation (aluminum) and diarrhea (magnesium) as potential side effects.

Q: Is there a maximum number of days to take Moxal Plus?

A: Official regulatory guidance states that the maximum recommended dosage should not be used for more than two weeks consecutively. If symptoms persist beyond this duration, this situation warrants further medical evaluation.

Q: Will Moxal Plus affect the results of blood tests?

A: Prolonged or high-dose use, particularly in individuals with impaired kidney function, can lead to the systemic accumulation of aluminum and magnesium, which are minerals measured via blood tests. The medicine is intended for limited use in individuals with impaired kidney function due to the potential for accumulating these minerals.

Q: How is Moxal Plus different from proton pump inhibitors (PPIs)?

A: Moxal Plus is classified as an antacid, meaning it works non-systemically by chemically neutralizing the stomach acid that is already present. This is different from proton pump inhibitors (PPIs), which are absorbed and work systemically to reduce the amount of acid the stomach produces over time.

Q: Does taking Moxal Plus affect blood sugar levels?

A: While the core antacid ingredients do not typically affect general blood sugar regulation, some formulations may contain excipients, such as sorbitol, that are relevant to patients with certain metabolic conditions, including Hereditary Fructose Intolerance. It is important for individuals with diabetes or other blood sugar concerns to review the full ingredient list.

Q: Why is the dosage for Moxal Plus sometimes listed in teaspoons or tablespoons?

A: Official labeling for the liquid suspension provides the recommended dose in teaspoonfuls (tsp), equating this measure to a volume in milliliters (mL). This is intended to guide administration using an appropriate measuring device, often a dosing spoon or cup.

Q: How quickly should I feel better after taking Moxal Plus?

A: Antacids are characterized by their rapid mechanism of action, neutralizing existing stomach acid quickly upon reaching the site of discomfort. The liquid formulation supports this by facilitating the rapid availability of the active ingredients.

Q: Why does Moxal Plus come in a suspension form?

A: The suspension form is designed to facilitate the rapid and uniform dispersion of the active ingredients throughout the stomach. This rapid dispersion helps the antacid components quickly neutralize acid, supporting prompt symptomatic relief.

Q: Why do some people say Moxal Plus makes them drowsy?

A: Official regulatory safety data does not list drowsiness or other central nervous system (CNS) effects among the commonly documented adverse reactions for this medicine.

Q: What are the different strengths of Moxal Plus?

A: Official regulatory documentation lists the specific strengths of the active ingredients contained within the product. Common liquid suspension strengths include formulations with a specific amount of aluminum hydroxide and magnesium hydroxide per standard dose volume.

Q: Is the relief from Moxal Plus long-lasting?

A: Antacids provide immediate but short-term relief. The medicine is typically intended for short-duration relief, as reflected by its administration schedule for episodic symptoms.

Q: Why would a doctor recommend Moxal Plus over a plain antacid?

A: The medicine is classified as an 'Antacid and Antiflatulence' agent because it is a combination product. It includes both acid-neutralizing ingredients and simethicone, an anti-gas agent, making it suitable for treating symptoms of both heartburn and gas/bloating concurrently.

Q: Can Moxal Plus be used for acid reflux at night?

A: Yes, official administration instructions recommend taking the medicine after meals and specifically include administration at bedtime for the relief of symptoms.

Q: Does Moxal Plus contain sodium?

A: Yes, regulatory labeling indicates that the medicine contains a small amount of sodium. This content is detailed in the 'Other Information' section of the official product information.

Q: What is the minimum age to take Moxal Plus?

A: The medicine is officially labeled and dosed for use in adults and children 12 years and older. For children under 12 years of age, the label requires consultation with a physician.

Q: What are the signs that Moxal Plus isn't working for me?

A: Official labeling instructs the user to 'Stop use and ask a doctor' if symptoms persist for more than two weeks. This indicates that symptomatic relief is inadequate and that further medical evaluation is necessary.

Q: Does Moxal Plus cause mineral deficiency over time?

A: Prolonged use or high doses of aluminum-containing antacids can interfere with the body's balance of electrolytes and minerals. Official warnings specifically note the risk of phosphate depletion ( hypophosphatemia), which is an electrolyte imbalance that can potentially lead to bone weakening.

Q: Is the product information leaflet for Moxal Plus easily accessible online?

A: Yes, the official labeling, which includes the summary of product characteristics and package insert, is generally available online through government regulatory sources such as FDA DailyMed and the European Medicines Agency (EMA).

How should Moxal Plus be stored and disposed of?

How to Store and Dispose of Moxal Plus

Storage Conditions

Moxal Plus suspension must be stored at a temperature below 30 C and should be protected from excess heat. Regulatory labeling strictly instructs users not to refrigerate or freeze the medicine. The bottle must be kept tightly closed to maintain its integrity, and the suspension should be shaken well before use.

Stability and Child Safety

The product must be used and subsequently disposed of 6 months after first opening the bottle. Moxal Plus must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Do not dispose of this medicine through wastewater or household trash. Unused or expired Moxal Plus must be discarded according to official instructions; users should ask a pharmacist for the correct procedure, which is intended to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Moxal Plus found in:

A-Z Index: